buprenorphine (byoo-pre-nor-feen)
|
|
- Evelyn Underwood
- 6 years ago
- Views:
Transcription
1 1 REMS High Alert buprenorphine (byoo-pre-nor-feen) Buprenex, Butrans, Subutex Classification Therapeutic: opioid analgesics Pharmacologic: opioid agonists/antagonists Schedule III Pregnancy Category C Indications IM, IV: Management of moderate to severe acute pain. Transdermal: Management of moderate to severe chronic pain in patients requiring use of a continuous aroundthe-clock opioid analgesic for an extended period of time. SL: Treatment of opioid dependence; suppresses withdrawal symptoms in opioid detoxification. Action Binds to opiate receptors in the CNS. Alters the perception of and response to painful stimuli while producing generalized CNS depression. Has partial antagonist properties that may result in opioid withdrawal in physically dependent patients when used as an analgesic. Therapeutic Effects: IM, IV, Transdermal: Decreased severity of pain. SL: Suppression of withdrawal symptoms during detoxification and maintenance from heroin or other opioids. Produces a relatively mild withdrawal compared to other agents. Pharmacokinetics Absorption: Well absorbed after IM and SL use; 15% of transdermal dose absorbed through skin; IV administration results in complete bioavailability. Distribution: Crosses the placenta; enters breast milk. CNS concentration is 15 25% of plasma. Protein Binding: 96%. Metabolism and Excretion: Mostly metabolized by the liver mostly via the CYP3A4 enzyme system; one metabolite is active; 70% excreted in feces; 27% excreted in urine. Half-life: 2 3 hr (parenteral); 26 hr (transdermal). TIME/ACTION PROFILE (analgesia) ROUTE ONSET PEAK DURATION IM 15 min 60 min 6 hr IV rapid lessthan 60 min 6 hr SL unknown unknown unknown Transdermal unknown unknown 7 days 4 5 hrin children Contraindications/Precautions Contraindicated in: Hypersensitivity; Significant respiratory depression (transdermal); Acute or severe bronchial asthma (transdermal); Paralytic ileus (transdermal); Acute, mild, intermittent, or postoperative pain (transdermal); Long QT syndrome (transdermal); Concurrent use of class I or III antiarrhythmics (transdermal); Lactation: Enters breast milk; avoid use or discontinue nursing. Use Cautiously in:qintracranial pressure; Severe renal, hepatic, or pulmonary disease; Hypothyroidism; Seizure disorders; Adrenal insufficiency; Alcoholism; Biliary tract disease; Acute pancreatitis; Debilitated patients (doseprequired); Undiagnosed abdominal pain; Prostatic hyperplasia; OB: Safety not established; neonatal withdrawal may occur in infants born to patients receiving SL buprenorphine during pregnancy; Pedi: Safety not established in children (sublingual and transdermal) or children 2 yr (parenteral); Geri: Doseprequired. Adverse Reactions/Side Effects CNS: confusion, dysphoria, hallucinations, sedation, dizziness, euphoria, floating feeling, headache, unusual dreams. EENT: blurred vision, diplopia, miosis (high doses). Resp: respiratory depression. CV: hypertension, hypotension, palpitations, QT interval prolongation (transdermal). GI: HEPATOTOXICITY, nausea, constipation, dry mouth, ileus, vomiting. GU: urinary retention. Derm: sweating, clammy feeling, erythema, pruritis, rash. Misc: ANAPHYLAXIS, physical dependence, psychologicaldependence, tolerance. Interactions Drug-Drug: Use of high-dose transdermal buprenorphine with class I antiarrhythmics or class I antiarrhythmics mayqrisk of QT interval prolongation; avoid concurrent use. Use with extreme caution in patients receiving MAO inhibitors (qcns and respiratory depression and hypotension pbuprenorphine dose by 50%; may need topmao inhibitor dose; do not use transdermal formulation
2 2 within 14 days of MAO inhibitor).qcns depression with alcohol, antihistamines, antidepressants, and sedative/hypnotics. Maypeffectiveness of other opioid analgesics. Inhibitors of the CYP3A4 enzyme system including itraconazole, ketoconazole, erythromycin, ritonavir, indinavir, saquinavir, atazanavir, or fosamprenavir mayqblood levels and effects; may need topbuprenorphine dose. Inducers of the CYP3A4 enzyme system including carbamazepine, rifampin, or phenytoin maypblood levels and effects; buprenorphine dose modification may be necessary during concurrent use. Concurrent abuse of buprenorphine and benzodiazepines may result in coma and death. Drug-Natural Products: Concomitant use of kava-kava, valerian, chamomile,or hops canqcns depression. Route/Dosage Analgesia IM, IV (Adults): 0.3 mg q 4 6 hr as needed. May repeat initial dose after 30 min (up to 0.3 mg q 4 hr or 0.6 mg q 6 hr); 0.6-mg doses should be given only IM. IM, IV (Children 2 12 yr): 2 6 mcg ( mg)/kg q 4 6 hr. Transdermal (Adults): Opioid-naive-Transdermal system delivering 5 20 mcg/ hr applied every 7 days. Initiate with 5 mcg/hr system; each dose titration may occur after 72 hr; do not exceed dose of 20 mcg/hr (due toqrisk of QT interval prolongation); Previously taking 30 mg/day of morphine or equivalent-initiate with 5 mcg/hr system; each dose titration may occur after 72 hr; do not exceed dose of 20 mcg/hr (due toqrisk of QT interval prolongation); apply patch every 7 days; Previously taking mg/day of morphine or equivalent-initiate with 10 mcg/hr system; each dose titration may occur after 72 hr; do not exceed dose of 20 mcg/hr (due toqrisk of QT interval prolongation); apply patch every 7 days; Previously taking 80 mg/day of morphine or equivalent Consider use of alternate analgesic. Hepatic Impairment Transdermal (Adults): Mild to moderate hepatic impairment-initiate with 5 mcg/hr system. Treatment of opioid dependence SL (Adults): mg/day as a single dose. NURSING IMPLICATIONS Assessment Pain: Assess type, location, and intensity of pain before and 1 hr after IM and 5 min (peak) after IV administration. When titrating opioid doses, increases of 25 50% should be administered until there is either a 50% reduction in the patient s pain rating on a numerical or visual analogue scale or the patient reports satisfactory pain relief. A repeat dose can be safely administered at the time of the peak if previous dose is ineffective and side effects are minimal. Single doses of 600 mcg (0.6 mg) should be administered IM. Patients requiring doses higher than 600 mcg (0.6 mg) should be converted to an opioid agonist. Buprenorphine is not recommended for prolonged use (except transdermal) or as first-line therapy for acute or cancer pain. An equianalgesic chart (see Appendix B) should be used when changing routes or when changing from one opioid to another. Assess level of consciousness, BP, pulse, and respirations before and periodically during administration. If respiratory rate is 10/min, assess level of sedation. Dose may need to be decreased by 25 50%. Buprenorphine mg has approximately equal analgesic and respiratory depressant effects to morphine 10 mg. Assess previous analgesic history. Antagonistic properties may induce withdrawal symptoms (vomiting, restlessness, abdominal cramps, increased BP and temperature) in patients who are physically dependent on opioid agonists. Symptoms may occur up to 15 days after discontinuation and persist for 1 2 wk. Buprenorphine has a lower potential for dependence than other opioids; however, prolonged use may lead to physical and psychological dependence and tolerance. This should not prevent patient from receiving adequate analgesia. Most patients receiving buprenorphine for pain do not develop psychological dependence. If tolerance develops, changing to an opioid agonist may be required to relieve pain. Assess bowel function routinely. Prevent constipation with increased intake of fluids and bulk, and laxatives to minimize constipating effects. Administer stimulant laxatives routinely if opioid use exceeds 2 3 days, unless contraindicated. Transdermal: Maintain frequent contact during periods of changing analgesic requirements, including initial titration, between the prescriber, other members of the healthcare team, the patient, and the caregiver/family. Treatment of Opioid Dependence: Assess patient for signs and symptoms of opioid withdrawal before and during therapy F.A. Davis Company
3 3 buprenorphine Lab Test Considerations: May causeqserum amylase and lipase levels. Monitor liver function tests prior to and periodically during therapy for opioid dependence. Toxicity and Overdose: If an opioid antagonist is required to reverse respiratory depression or coma, naloxone (Narcan) is the antidote. Dilute the 0.4-mg ampule of naloxone in 10 ml of 0.9% NaCl and administer 0.5 ml (0.02 mg) by direct IV push every 2 min. For children and patients weighing 40 kg, dilute 0.1 mg of naloxone in 10 ml of 0.9% NaCl for a concentration of 10 mcg/ml and administer 0.5 mcg/kg every 1 2 min. Titrate dose to avoid withdrawal, seizures, and severe pain. Naloxone may not completely reverse respiratory depressant effects of buprenorphine; may require mechanical ventilation, oxygen, IV fluids, and vasopressors. Potential Nursing Diagnoses Acute pain (Indications) Risk for injury (Side Effects) Ineffective coping (Indications) Implementation High Alert: Accidental overdose of opioid analgesics has resulted in fatalities. Before administering, clarify all ambiguous orders; have second practitioner independently check original order, dose calculations, route of administration, and infusion pump programming. Pain: Explain therapeutic value of medication before administration to enhance the analgesic effect. Regularly administered doses may be more effective than prn administration. Analgesic is more effective if given before pain becomes severe. Coadministration with nonopioid analgesics has additive effects and may permit lower opioid doses. SL: Administer sublingually. Usually takes 2 10 min for tablets to dissolve. If more than one tablet is prescribed, place multiple tablets under the tongue or 2 at a time until all tablets are dissolved. Do not chew or swallow; decreases amount of medication absorbed. IM: Administer IM injections deep into well-developed muscle. Rotate sites of injections. IV Administration ph: Direct IV: May give IV undiluted. High Alert: Administer slowly. Rapid administration may cause respiratory depression, hypotension, and cardiac arrest. Rate: Give over at least 2 minutes. Y-Site Compatibility: acetaminophen, acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, ascorbic acid, atracurium, atropine, azithromycin, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, butorphanol, calcium chloride, calcium gluconate, carboplatin, carmustine, cefazolin, cefepime, cefoperazone, ceftaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxome, cefuroxime, chloramphenicol, chlorpromazine, cisatracurium, cisplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cyclosporine, cytarabine, dactinomycin, daptomycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dolasetron, dopamine, doxacurium, doxorubicin, doxycycline, enalaprilat, ephedrine, epinephrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, foscarnet, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hetastarch, hydrocortisone, idarubicin, ifosfamide, imipenem/cilastatin, insulin, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methotrexate, methyldopate, methylprednisolone, metoclopramide, metoprolol, metronidazole, midazolam, milrinone, mitoxantrone, morphine, multivitamins, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, nicardipine, nitroglycerine, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pamidronate, pancuronium, papaverine, pemetrexed, penicillin G, pentamidine, pentazocine, phentolamine, phenylephrine, phytonadione, piperacillin/tazobactam, potassium acetate, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, propranolol, protamine, pyridoxime, quinupristin/dalfopristin, ranitidine, remifentanil, rituximab, rocuronium, sodium acetate, streptokinase, succinylcholine, sufentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin/clavulanate, tigecyc-
4 4 line, tirofiban, tobramycin, tolazoline, trastuzumab, vancomycin, vasopressin, vecuronium, verapamil, vinblastine, vincristine, vinorelbine, voriconazole, zoledronic acid. Y-Site Incompatibility: alemtuzumab, aminophylline, amphotericin B cholesteryl, ampicillin, azathioprine, dantrolene, diazepam, diazoxide, doxorubicin liposome, fluorouracil, indomethacin, pantoprazole, pentobarbital, phenobarbital, phenytoin, sodium bicarbonate, trimethoprim/sulfamethoxazole. Solution Compatibility: 0.9% NaCl, D5W, D5/0.9% NaCl, lactated Ringer s injection, Ringer s injection. Transdermal: Buprenorphine may cause withdrawal in patients who are already taking opioids. For conversion from other opioids to buprenorphine transdermal, taper current around-the-clock opioids for up to 7 days to no more than 30 mg of morphine or equivalent per day before beginning treatment with buprenorphine transdermal. May use short-acting analgesics as needed until analgesic efficacy with buprenorphine transdermal is attained. Buprenorphine transdermal may not provide adequate analgesia for patients requiring greater than 80 mg/day oral morphine equivalents. Apply system to flat, nonirritated, and nonirradiated site on the upper outer arm, upper chest, upper back or the side of the chest. If skin preparation is necessary, use clear water and clip, do not shave, hair. Allow skin to dry completely before application. Apply immediately after removing from package. Do not alter the system (i.e., cut) in any way before application. Remove liner from adhesive layer and press firmly in place with palm of hand for 30 sec, especially around the edges, to make sure contact is complete. Remove used system and fold so that adhesive edges are together. Flush system down toilet immediately on removal or follow the institutional policy. Apply new system to a different site. After removal, wait a minimum of 3 weeks before applying to the same site. To discontinue, taper dose gradually to prevent signs and symptoms of withdrawal; consider introduction of immediate-release opioid medication. Treatment of Opioid Dependence: Must be prescribed by health care professional with special training. Induction is usually started with buprenorphine (Subutex) over 3 4 days. Initial dose should be administered at least 4 hr after last opioid dose and preferably when early signs of opioid withdrawal appear. Once patient is on a stable dose, maintenance therapy with buprenorphine/naloxone (Suboxone) is preferred for continued, unsupervised treatment. Patient/Family Teaching Medication may cause drowsiness or dizziness. Advise patient to call for assistance when ambulating and to avoid driving or other activities requiring alertness until response to medication is known. Advise patient to avoid concurrent use of alcohol or other CNS depressants. Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking any OTC medications concurrently with this therapy. Advise patient to notify health care professional if pregnancy is planned or suspected, or if breast feeding. Pain: Instruct patient on how and when to ask for pain medication. Encourage patients on bedrest to turn, cough, and deep-breathe every 2 hr to prevent atelectasis. Instruct patient to change positions slowly to minimize orthostatic hypotension. Advise patient that good oral hygiene, frequent mouth rinses, and sugarless gum or candy may decrease dry mouth. Transdermal: Instruct patient in correct method for application, removal, storage, and disposal of transdermal system. Wear patches for 7 days. May be worn while bathing, showering, or swimming. Do not discontinue or change dose without consulting health care professional. Instruct patient to read the Medication Guide prior to starting and with each Rx refill. Advise patients and caregivers/family members of the potential side effects. Instruct patient to notify health care professional if pain is not controlled or if bothersome side effects occur. Contact immediately if difficulty or changes in breathing, unusual deep sighing breathing slow or shallow breathing, new or unusual snoring, slow heartbeat, severe sleepiness, cold, clammy skin, feeling faint, dizzy, confused, or cannot think, walk, or talk normally, or if swelling or blistering around patch occurs. Advise patient that fever, electric blankets, heating pads, saunas, hot tubs, and heated water beds increase the release of fentanyl from the patch. Advise patient referred for MRI test to discuss patch with referring health careprofessional and MRI facility to determine if removal of patch is necessary prior to test and for directions for replacing patch. Opioid Dependence: Instruct patient in the correct use of medication; directions for use must be followed exactly. Medication must be used regularly, not occasionally. Take missed doses as soon as remembered; if almost time for next dose, skip missed dose and return to regular dosing schedule. Do not take 2 doses 2015 F.A. Davis Company
5 5 buprenorphine at once unless directed by health care professional. Do not discontinue use without consulting health care professional; abrupt discontinuation may cause withdrawal symptoms. If medication is discontinued, flush unused tablets down the toilet. Caution patient that buprenorphine may be a target for people who abuse drugs; store medications in a safe place to protect them from theft. Selling or giving this medication to others is against the law. Caution patient that injection of Suboxone can lead to severe withdrawal symptoms. Advise patient if admitted to the emergency room to inform treating physician and emergency room staff of physical dependence on opioids and of treatment regimen. Advise patient to notify health care professional promptly if faintness, dizziness, confusion, slowed breathing, skin or whites of eyes turn yellow, urine turns dark, light-colored stools, decreased appetite, nausea, or abdominal pain occur. Evaluation/Desired Outcomes Decrease in severity of pain without a significant alteration in level of consciousness or respiratory status. Suppression of withdrawal symptoms during detoxification and maintenance from heroin or other opioids. Why was this drug prescribed for your patient?
Share the important information in this Medication Guide with members of your household.
Medication Guide BUPRENORPHINE (BUE-pre-NOR-feen) and NALOXONE (nal-ox-one) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children.
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency
More informationANESTHESIA DRUG REVIEW
ANESTHESIA REVIEW CAPA S 39 TH ANNUAL CONFERENCE PALM SPRINGS OCTOBER 10, 2015 ROBERT F. KOPEL, MD, FACP, FCCP HOAG HOSPITAL CARDIAC ANESTHESIOLOGIST ASSISTANT CLINICAL PROFESSOR UCLA SCHOOL OF MEDICINE
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationMEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII)
MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a
More informationRegional. Parenteral Manual. Usage Guidelines
Regional Parenteral Manual Usage Guidelines 1. Background and Objectives... 2 2. Off-Label Use of Drugs... 3 3. Abbreviations for Monographs and Definitions... 4 3.1 Abbreviations for Regional Parenteral
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationMedication Guide Fentanyl transdermal system, CII Rx Only Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid
Medication Guide Fentanyl transdermal system, CII Rx Only Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough
More informationAgonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone
Opioid Definition All drugs, natural or synthetic, that bind to opiate receptors Agonists: morphine, fentanyl Agonists-Antagonists: nalbuphine Antagonists: naloxone Opioid agonists increase pain threshold
More informationPatient Information Leaflet
Page 25 Patient Information Leaflet PATIENT INFORMATION SUBOXONE (sub-ox-own) (buprenorphine HCl/naloxone HCl dihydrate, sublingual tablet) (C*) SUBUTEX (SUB-u-tex) (buprenorphine HCl, sublingual tablet)
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental
More informationSlide 1. Slide 2. Slide 3. Opioid (Narcotic) Analgesics and Antagonists. Lesson 6.1. Lesson 6.1. Opioid (Narcotic) Analgesics and Antagonists
Slide 1 Opioid (Narcotic) Analgesics and Antagonists Chapter 6 1 Slide 2 Lesson 6.1 Opioid (Narcotic) Analgesics and Antagonists 1. Explain the classification, mechanism of action, and pharmacokinetics
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Film for sublingual or buccal administration (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental
More informationSUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION
SUBOXONE (buprenorphine and naloxone) sublingual film (CIII) IMPORTANT SAFETY INFORMATION What is the most important information I should know about SUBOXONE Film? Keep SUBOXONE Film in a secure place
More informationMedication Guide Fentanyl Transdermal System, CII (fĕn tə-nĭl) Fentanyl transdermal system is:
Medication Guide Fentanyl Transdermal System, CII (fĕn tə-nĭl) Fentanyl transdermal system is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More informationFentanyl Transdermal System Page 1 of mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr, 100 mcg/hr Prescribing Information
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use fentanyl transdermal system safely and effectively. See full prescribing information for fentanyl
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationMEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (MOR feen SUL fate) (CII) Oral Solution IMPORTANT: Keep morphine sulfate oral solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationFENTANYL transdermal system, CII Initial U.S. Approval: 1968
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FENTANYL TRANSDERMAL SYSTEM safely and effectively. See full prescribing information for FENTANYL
More information4.4 Special warnings and precautions for use
SUMMARY OF PRODUCT CHARACTERISTICS 4.3 Contraindications Durogesic is contraindicated in patients with known hypersensitivity to fentanyl or to the excipients present in the patch. Acute or postoperative
More informationActive Pharmaceutical Ingredient (API) List List Updated March 1st, 2019
5-Fluorouracil 5-FU, Fluorouracil Stability Indicating HPLC-UV USP 7-keto DHEA Stability Indicating HPLC-UV Medisca Tier 1 Acetaminophen Stability Indicating HPLC-UV USP Adenosine Alprostadil PGE-1, Prostaglandin
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More informationDrug Max dose approved for IVP Dilution Rate Monitoring Parameters. Dilution not necessary (Available in prefilled syringe)
Drug Max dose approved for IVP Dilution Rate Monitoring Parameters Acetazolamide 500 mg Reconstitute with at least 5ml sterile water (max concentration should not exceed 100mg/ml) 100-500 mg/min Hypotension
More informationAND ADMINISTRATION DURAGESIC
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use DURAGESIC safely and effectively. See full prescribing information for DURAGESIC. DURAGESIC (fentanyl
More informationSubstitution Therapy for Opioid Use Disorder The Role of Suboxone
Substitution Therapy for Opioid Use Disorder The Role of Suboxone Methadone/Buprenorphine 101 Workshop, December 10, 2016 Leslie Lappalainen, MD, CCFP, dip ABAM Prepared by Mandy Manak, MD, ABAM, CCSAM
More informationAlaris System Profile Report RELEASED. Stepdown. VUMC - 3/18/ :20 Page 1 of 19 VUMC O, 018d997b6-R
Alaris System Profile Report RELEASED Stepdown VUMC - 3/18/2013 09:20 Page 1 of 19 1. Current Data Set Status Data Set Name Hospital Name Data Set ID Data Set Status VUMC 9.4 2013 O VUMC 018d997b6-R Released
More informationMEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only
MEDICATION GUIDE MORPHINE Sulfate Oral Solution (mor-pheen) CII Rx only IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency
More informationAdhere to instructions concerning administration and disposal of fentanyl transdermal system.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Fentanyl Transdermal System safely and effectively. See full prescribing information for Fentanyl
More informationCORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/ January 2013
CORE SAFETY PROFILE OXYCODONE HYDROCHLORIDE NL/H/PSUR/0054/001 16 January 2013 1 4.2 Posology and method of administration (safety aspects only) Posology Elderly patients For oral preparations A dose adjustment
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationWhat is the most important information I should know about Morphine Sulfate Oral Solution?
Medication Guide MORPHINE SULFATE (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationMEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution
MEDICATION GUIDE Morphine Sulfate (mor-pheen) (CII) Oral Solution IMPORTANT: Keep Morphine Sulfate Oral Solution in a safe place away from children. Accidental use by a child is a medical emergency and
More informationFOLLOW DIRECTIONS. How to Use Methadone Safely. U.S. Department of Health & Human Services
FOLLOW DIRECTIONS How to Use Methadone Safely U.S. Department of Health & Human Services Substance Abuse and Mental Health Services Administration Food and Drug Administration Methadone Methadone provides
More informationELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY
ELECTRONIC HEALTH RECORD (EHR) ENHANCEMENTS FOR MARCH 15, 2016 SUMMARY Problem Opening PACS Images on ipads or ibooks has Been Fixed Changes have been made in PROD to enable user credentials to be passed
More informationUTMB DEPARTMENT OF PHARMACY POLICY AND PROCEDURES Section Medication Use ADMINISTRATION OF MEDICATION BY IV PUSH
Page 1 of 8 ADMINISTRATION OF MEDICATION BY IV PUSH AUDIENCE POLICY This document is directed to Registered Nurses (RNs), Licensed Vocational Nurses (LVN s), and physicians. The following delineates the
More informationPART III: CONSUMER INFORMATION ABOUT THIS MEDICATION. APO-FENTANYL MATRIX fentanyl transdermal system
PART III: CONSUMER INFORMATION APO-FENTANYL MATRIX fentanyl transdermal system This leaflet is Part III of a three-part "Product Monograph" published when APO-FENTANYL MATRIX was approved for sale in Canada
More informationMEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP
MEDICATION GUIDE Oxycodone Hydrochloride (ox-ee-co-dohn) (CII) Oral Solution, USP IMPORTANT: Keep oxycodone hydrochloride oral solution in a safe place away from children. Accidental use by a child is
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. N FENTANYL PATCH Fentanyl Transdermal Patches (Matrix)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION N FENTANYL PATCH Fentanyl Transdermal Patches (Matrix) Read this carefully before you start taking Fentanyl Patch and
More informationNursing Process Focus: Patients Receiving Levodopa (Larodopa)
Assessment Prior to administration: Obtain complete health history including allergies, drug history and possible drug interactions. Obtain baseline evaluation of severity of Parkinson s disease to determine
More informationPOLICY and PROCEDURE
Misericordia Community Hospital Administration of Intravenous FentaNYL During Labour POLICY and PROCEDURE Labour and Delivery Manual Original Date Revised Date Approved by: Director, Women s Health, Covenant
More informationCURRENT DRUG SHORTAGES (through February 22, 2013) CURRENT & ONGOING SHORTAGES CRITICAL SHORTAGES
CURRENT DRUG SHORTAGES (through February 22, 2013) CRITICAL SHORTAGES Acetylcysteine Inhalation Analgesic Buprenorphine Caffeine and Ergotamine Acyclovir Meperidine Injection Adenosine Amino Acid Products
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationFacts About BELBUCA (buprenorphine) Buccal Film
Facts About BELBUCA (buprenorphine) Buccal Film Indication BELBUCA is a recent FDA-approved medication for the treatment of chronic pain severe enough to require daily, around-the-clock, long-term opioid
More informationDoctor Discussion Guide
Doctor Discussion Guide Getting the pain relief you need to stay active is important. Keeping track of your symptoms can help you and your healthcare provider determine if there is a need to adjust your
More informationA Pharmacist s Guide
A Pharmacist s Guide Help patients for the week ahead Please read accompanying Full Prescribing Information, including Boxed Warning on page 2 and page 9. Indications and Usage Butrans (buprenorphine)
More informationORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA
ORAL TRANSMUCOSAL AND NASAL FENTANYL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: Fentanyl by oral transmucosal and nasal delivery Actiq (fentanyl citrate) lozenge on a handle 200,
More informationOndansetron blocks the actions of chemicals in the body that can trigger nausea and vomiting.
1 of 6 6/10/2016 4:54 PM Generic Name: ondansetron (oral) (on DAN se tron) Brand Names: Zofran, Zofran ODT, Zuplenz What is ondansetron? Ondansetron blocks the actions of chemicals in the body that can
More informationPackage leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate
Package leaflet: Information for the patient Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate Read all of this leaflet carefully before you start using this medicine because
More information6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center
RATE Abciximab (Reopro) Alteplase (tpa, Activase) All units 6S and 6W ONLY Platelet aggregation inhibitor Thrombolytic agent Bolus: 0.25 mg/kg IV over 5 min Infusion: 0.125 0.9 mg/kg (max 90 mg); 10% of
More informationPATIENT INFORMATION LEAFLET AMLOC RANGE
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: AMLOC 5 mg tablets AMLOC 10 mg tablet Read all of this leaflet carefully before you start taking AMLOC. Keep this leaflet. You may need to read it
More informationGuide for Patients and Caregivers
N FENTORA Fentanyl Buccal/Sublingual Effervescent Tablets 100 mcg, 200 mcg, 400 mcg, 600 mcg, and 800 mcg fentanyl as fentanyl citrate Opioid Analgesic Guide for Patients and Caregivers Manufactured for:
More informationPART 1.B SPC, LABELLING AND PACKAGE LEAFLET
TRAMADOG, solution for injection Decentralised Procedure D195 February 2018 V3 Tramadol HCl 50 mg/ml Part 1.B SPC, Labelling and Package Leaflet PART 1.B SPC, LABELLING AND PACKAGE LEAFLET 1B- 1 ANNEX
More informationMidazolam Injection Midazolam
Midazolam Injection Midazolam Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Midazolam Injection. It does not contain all the available information.
More informationLearn how MORPHABOND ER can help manage your pain
Your healthcare provider has prescribed Learn how can help manage your pain What is? MORPHABOND ER (morphine sulfate) extended-release tablets, CII is a strong prescription pain medicine that contains
More informationdisease or in clients who consume alcohol on a regular basis. bilirubin
NON-OPIOID Acetaminophen(Tylenol) Therapeutic class: Analgesic, antipyretic Aspirin (ASA, Acetylsalicylic Acid) Analgesic, NSAID, antipyretic Non-Opioid Analgesics COMMON USES WHAT I NEED TO KNOW AS A
More informationMEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution
MEDICATION GUIDE CODEINE SULFATE (koh-deen) CII Oral Solution IMPORTANT: Do not give CODEINE Sulfate Oral Solution to a child to treat pain after tonsillectomy or adenoidectomy surgery. When you take CODEINE
More informationNORVASC 5 mg and 10 mg tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER NORVASC 5 mg and 10 mg tablets AMLODIPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationVI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:
VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic
More informationMEDICATION GUIDE. ACTIQ (AK-tik) CII (fentanyl citrate) oral transmucosal lozenge 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg
MEDICATION GUIDE ACTIQ (AK-tik) CII (fentanyl citrate) oral transmucosal lozenge 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1200 mcg, 1600 mcg IMPORTANT: Do not use ACTIQ unless you are regularly using another
More informationOverview of Essentials of Pain Management. Updated 11/2016
0 Overview of Essentials of Pain Management Updated 11/2016 1 Overview of Essentials of Pain Management 1. Assess pain intensity on a 0 10 scale in which 0 = no pain at all and 10 = the worst pain imaginable.
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve 50 mg/ml solution for injection for dogs (AT, BE, BG, CY, CZ, DE, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO,
More informationSummary of Product Characteristics
Summary of Product Characteristics Product Summary 1. Trade Name of the Medicinal Product Durogesic DTrans 12/25/50/75/100 Transdermal Patch 2. Qualitative and Quantitative Composition Each Durogesic DTrans
More informationThis leaflet answers some common questions about Momex SR Tablets.
Momex SR Modified (Sustained) Release Tablets [Morphine sulphate] CONSUMER MEDICINE INFORMATION What is in this leaflet This leaflet answers some common questions about Momex SR Tablets. It does not contain
More informationCustomer Service: Shop online at
Effective May 1, 2017 Item Number Changes for Pharmaceuticals Due to changes in regulatory requirements, effective May 1, 2017, some of our pharmaceuticals' units of sale will change. The table below outlines
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationIntroductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs
Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available
More informationTuscarawas County Health Department. Vivitrol Treatment Consent
Tuscarawas County Health Department Vivitrol Treatment Consent I. Vivitrol Medication Guide: a. VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) b. Read this Medication Guide
More informationB. Long-acting/Extended-release Opioids
4 Opioid tolerance is assumed in patients already taking fentanyl 25 mcg/hr OR daily doses of the following oral agents for 1 week: 60 mg oral morphine, 30 mg oxycodone, 8 mg hydromorphone, 25 mg of oxymorphone
More informationDr M H Mosaddegh Pharm D, PhD
Dr M H Mosaddegh Pharm D, PhD opioid All compounds related to opium Opium derived from opos, Greek word of juice, juice of opium poppy, Papaver somniferum Opiates Drugs derived from opium. Included the
More informationPatient Guide For Actiq (fentanyl citrate) Lozenges
Patient Guide For Actiq (fentanyl citrate) Lozenges 1 You have been prescribed Actiq (fentanyl citrate) lozenge for your Breakthrough Cancer Pain (BTcP) Important Do not use Actiq unless you have been
More informationBuprenorphine Patch (Transtec Patch)
NHS Greater Glasgow And Clyde Pain Management Service Information for Adult Patients who are Prescribed Buprenorphine Patch (Transtec Patch) For the Treatment of Pain Contents Page What is a transtec patch?...
More informationLess pain in my life helps me get back to living.
Eligible patients pay as little as $0 for BELBUCA Less pain in my life helps me get back to living. BELBUCA is: RETHINK RELIEF A strong prescription pain medicine that contains an opioid (narcotic) that
More informationAppendix 5: Hepatic impairment
Appendix 5: Hepatic impairment Liver disease may alter the response to drugs. However, the hepatic reserve appears to be large and liver disease has to be severe before important changes in drug metabolism
More informationConcomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.
Avifanz Tablet Description Avifanz is the brand name for Efavirenz. Efavirenz, a synthetic antiretroviral agent, is a non-nucleoside reverse transcriptase inhibitor. While Efavirenz is pharmacologically
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationCollaboration for REMS Education
Presented by CO*RE Collaboration for Relevant Presented Educationby CO*RE www.core-rems.org Collaboration for REMS Education www.corerems.org Collaborative for REMS Education CO*RE 2014 GENERAL DRUG INFORMATION
More informationADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments
ADENOSINE Paroxysmal SVT 1 st Dose 6 mg rapid IV 2 nd & 3 rd Doses 12 mg rapid IV push Follow each dose with rapid bolus of 20 ml NS May cause transient heart block or asystole. Side effects include chest
More informationDon't forget to see our PharmaTags: Sterile Medication Labels at
PharmaTags: Anaesthesia Roll Labels Order Form Toll Free: 1 888 299 2661 PRICING: 10 Rolls Same Medication Label=$5.75/Roll or $57.50 Box Mix and Match 10 Rolls= $6.25/Roll or $62.50/Box Minimum Order
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationWhy do I need to use Fentanyl Patches?
Why do I need to use Fentanyl Patches? Fentanyl patches are used to control on-going moderate to severe pain. They are not used for pain that only lasts for a short time. You will be given different, quick
More informationPART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION
PART III: PATIENT MEDICATION INFORMATION READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION N HYCODAN (hydrocodone bitartrate) Tablets and Syrup Read this carefully before
More informationAdult Drug Reference. Dopamine Drip Chart. Pediatric Drug Reference. Pediatric Drug Dosage Charts DRUG REFERENCES
Adult Drug Reference Dopamine Drip Chart Pediatric Drug Reference Pediatric Drug Dosage Charts DRUG REFERENCES ADULT DRUG REFERENCE Drug Indication Adult Dosage Precautions / Comments ADENOSINE Paroxysmal
More information6. Never give SUBSYS to anyone else, even if they have the same symptoms you have. It may harm them or even cause death.
Medication Guide SUBSYS (sub sis) CII (fentanyl) sublingual spray 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg IMPORTANT: Do not use SUBSYS unless you are regularly using another opioid pain medicine around-the-clock
More informationANNEX III LABELLING AND PACKAGE LEAFLET
ANNEX III LABELLING AND PACKAGE LEAFLET 1 A. LABELLING 2 PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE Outer carton Multi-pack 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Tralieve
More information*Monitor for significant side effects, especially symptoms of neurological or cardiovascular events.
Assessment Prior to administration: Obtain complete health history including allergies, drug history, and possible drug reactions Assess reason for drug administration such as presence/history of anemia
More informationXTAMPZA ER (oxycodone) extended-release capsules, for oral use, CII Initial U.S. Approval: 1950
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XTAMPZA ER safely and effectively. See full prescribing information for XTAMPZA ER. XTAMPZA ER (oxycodone)
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationMedication Guide BELBUCATM (bel-bue-kuh) (buprenorphine) buccal film, CIII BELBUCA is:
Medication Guide BELBUCA TM (bel-bue-kuh) (buprenorphine) buccal film, CIII BELBUCA is: A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage pain severe enough
More informationOP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4
Opioid MCQ OP01 [Mar96] With regards to pethidine s physical properties: A. It has an octanol coefficient of 10 B. It has a pka of 8.4 OP02 [Mar96] Which factor does NOT predispose to bradycardia with
More informationAppendix A: Pharmacologic approaches to pain management during MVA
Pain medication Though the medications shown below are commonly used for pain management during uterine evacuation, many other options exist. This table does not cover general anesthetic agents. Both anxiolytics
More informationAdult Critical Care Intravenous Infusions Titration Protocol
Adult Critical Care Intravenous Infusions Protocol Nursing staff to titrate drip to achieve goal ordered by provider in assigned time intervals. Amiodarone (Pacerone ) Argatroban Non-heparin anticoagulant
More informationCare for patients with Neurological disorders
King Saud University College of Nursing Medical Surgical Department Application of Adult Health Nursing Skills ( NUR 317 ) Care for patients with Neurological disorders Outline; EEG Overview. Nursing Interventions;
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationRE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act
22 January 2019 RE: Shortage of DBL MORPHINE SULFATE 30mg/1mL injection BP ampoule and alternative supply arrangement under Section 19A of the Therapeutic Goods Act Dear Healthcare Professional, This notification
More information